靶向药治疗晚期肺癌临床效果及不良反应探讨  

The Clinical Effects and Adverse Reactions of Targeted Drugs in the Treatment of Advanced Lung Cancer

作　　者：焦赫 JIAO He(Department of Respiratory and Critical Care Medicine,Fourth Hospital of Daqing City,Daqing,Heilongjiang Province,163000 China)

机构地区：[1]大庆市第四医院呼吸与危重症医学科,黑龙江大庆163000

出　　处：《系统医学》2021年第17期41-43,共3页Systems Medicine

摘　　要：目的对靶向药物治疗晚期肺癌的临床疗效及不良反应进行分析探讨。方法将2018年1月—2019年1月在该院接受治疗的90例晚期肺癌患者随机分为两组,对照组45例患者采用常规化疗治疗,观察组45例患者行靶向药物治疗,对比两组治疗效果及不良反应发生率。结果观察组治疗有效率为64.44%,显著高于对照组的42.22%,差异有统计学意义(χ^(2)=8.927,P<0.05)。观察组健康状况调查简表(SF-36)评分显著高于对照组,差异有统计学意义(t=8.893、15.363、25.039、21.026、13.649,P<0.05)。观察组腹泻、皮疹、口腔炎及血液系统毒性反应等不良反应发生率显著低于对照组,差异有统计学意义(χ^(2)=5.075、4.865、9.680、4.464,P<0.05)。结论对晚期肺癌采用靶向药物治疗,能够提高治疗效果,改善患者生活质量,降低不良反应发生率,改善患者预后,值得临床应用推广。Objective To analyze the efficacy and adverse reactions of targeted drugs in the treatment of advanced lung cancer.Methods A total of 90 patients with advanced lung cancer who received treatment in the hospital from January 2018 to January 2019 were randomly divided into two groups.45 patients in the control group received conventional chemotherapy,and 45 patients in the observation group received targeted drug therapy.The therapeutic effect and incidence of adverse reactions were compared between the two groups.Results The effective rate of treatment in the observation group was 64.44%,which was significantly higher than 42.22%in the control group,the difference was statistically significant(χ^(2)=8.927,P<0.05).The SF-36 score of the observation group was significantly higher than that of the control group,the difference was statistically significant(t=8.893,15.363,25.039,21.026,13.649,P<0.05).The incidence of adverse reactions such as diarrhea,rash,stomatitis and hematological toxicity in the observation group was significantly lower than that of the control group,the difference was statistically significant(χ^(2)=5.075,4.865,9.680,4.464,P<0.05).Conclusion Targeted drug therapy for advanced lung cancer can improve the therapeutic effect,improve the quality of life of patients,reduce the incidence of adverse reactions,and improve the prognosis of patients,which is worthy of clinical application and popularization.

关 键 词：肺癌 特罗凯 分子靶向 抗肿瘤活性 

分 类 号：R59[医药卫生—内科学]